Novartis stock trades steady as oncology pipeline and recent earnings shape investor focus

Novartis AG (ISIN CH0012005267) stock represents one of the larger European healthcare names, backed by substantial prescription-drug revenue and a broad late-stage pipeline, while investors weigh recent earnings trends and the reshaped portfolio after the Sandoz spin-off.

According to publicly available company disclosures for fiscal 2023, Novartis reported total net sales in the area of roughly tens of billions of US dollars, with Innovative Medicines contributing the clear majority and oncology therapies such as Kisqali, Pluvicto, and Scemblix featuring among key growth drivers, underpinning the cash flows that help support the stock’s valuation.

Recent quarterly information for 2024 from Novartis’ investor communication shows that the group continues to grow core operating income and core earnings per share, supported by targeted cost-efficiency measures and a stronger focus on high-margin innovative products after the separation of the generics unit Sandoz, which has changed the group’s earnings mix and risk profile.

Revenue growth and margin trends

In fiscal 2023, Novartis recorded net sales in the range of approximately $45 billion, and company reporting indicated that core operating income rose by around mid-single-digit percentages compared with 2022, reflecting both topline growth and ongoing productivity initiatives within manufacturing and commercial operations.

Company materials for fiscal 2022 had shown net sales slightly lower than in 2023, so the 2023 figure represents a year-on-year improvement, with growth concentrated in oncology and immunology, while established cardiovascular and ophthalmology portfolios provided durable, though slower, contributions relative to the faster-growing cancer medicines.

Within this performance, core operating margin improved modestly between 2022 and 2023, with Novartis highlighting that its margin progression was driven by a greater share of revenue from innovative therapies and disciplined resource allocation, an evolution which investors often interpret as supportive for long-term earnings power and potentially for dividend sustainability.

Core EPS comparison and cash generation

Novartis’ reporting for fiscal 2023 noted core earnings per share in the mid-single-digit US-dollar range, up from the prior year by a measurable percentage, signaling that beyond revenue growth the company is converting sales into profit with some efficiency gains and lower impact from legacy restructuring charges.

This improvement compared with 2022 core EPS can be seen in the context of ongoing portfolio optimization; Novartis has exited certain non-core assets over recent years, and the more streamlined group yields stronger profitability metrics, which many market observers consider an important element in justifying the stock’s current price-to-earnings multiples.

Cash flow from operating activities also remained robust over the last two fiscal years, with company data for fiscal 2023 indicating operating cash flow in the tens of billions of US dollars, broadly comparable to 2022 levels, enabling continued investment in research and development, selective bolt-on deals, and shareholder returns via dividends and share repurchases.

Oncology portfolio and pipeline focus

Within oncology, Novartis highlights several products as drivers of recent revenue performance, including breast-cancer therapy Kisqali, radioligand therapy Pluvicto for prostate cancer, and chronic myeloid leukemia therapy Scemblix, each contributing to the year-on-year net sales increases reported for 2023 and early 2024.

Company information indicates that revenue from key oncology brands has grown at double-digit rates in recent reporting periods, with Kisqali and Pluvicto in particular gaining share in their respective indications, reinforcing the narrative that Novartis’ focus on targeted therapies and advanced modalities is gradually shifting its revenue base toward higher-growth segments.

Beyond currently marketed products, Novartis maintains a pipeline with numerous phase III programs in oncology and immunology; these late-stage candidates represent potential future revenue streams that could, if successfully approved and commercialized, extend growth beyond the current horizon implied by existing guidance ranges.

Product spotlight Kisqali

A representative product within Novartis’ oncology franchise is Kisqali, a CDK4/6 inhibitor indicated for hormone receptor positive, HER2 negative advanced or metastatic breast cancer, which has been cited in recent company materials as delivering strong prescription trends and forming a significant pillar of oncology net sales.

In recent periods, reported sales for Kisqali have risen meaningfully compared with the prior year, reflecting expanded physician adoption and broader market penetration across key geographies in Europe, North America, and selected Asia-Pacific markets where the drug is approved.

For Novartis, the performance of Kisqali illustrates the strategic emphasis on targeted cancer therapies with durable demand profiles, which can support both overall revenue growth and margin resilience, given the typical pricing and reimbursement structures in major developed healthcare systems.

Novartis stock and market context

Novartis stock is listed on SIX Swiss Exchange in Zurich under the ticker NOVN, and also trades via American Depositary Receipts in the United States, providing broader access for international investors seeking exposure to a large-cap European pharmaceutical name.

Publicly available market-data services indicate that Novartis shares currently trade at a level that reflects a market capitalization in the tens of billions of Swiss francs, positioning the company among the more substantial constituents of Swiss and European equity indices.

As a major healthcare stock, Novartis is often compared with global peers in terms of price-to-earnings ratios, dividend yield, and pipeline strength; its combination of stable cash flow, an oncology-focused growth engine, and disciplined capital allocation shapes how investors assess the balance between defensive qualities and potential upside.